Furthermore drugs may function as predicted in one population of patients whilst in others it may lead to an adverse drug reaction (ADR). In the US it is estimated that over 2 million people are hospitalised and 100,000 die each year from ADR.
The reason for this differential of action is due to a person’s specific genetic make up which allows for a difference in how a drug is metabolised. The new discipline of pharmacogenomics investigated this all too important interaction between a putative pharmacological agent and persons genome. The underlying aim of pharmacogenomics would be to tailor a drug to a person’s genes, ushering in the era of personalized medicine.
The development of pharmacogenomics as a routine part of drug discovery will generate large and sustainable revenues for the drug industry - BUT HOW MUCH? Find out by reading this exclusive report.
There are other aspects to pharmacogenomics which includes the technical part of this new discipline: such as
* Bioinformatics
* DNA Microarrays
It will provide a detailed analyses of these markets including, revenues, growth rates, companies involved and new developments.
Complete with tables, news, insights, the latest developments and a complete survey of the pharmacogenomics market and research arena. Pharmacogenomics will most likely become the dominant drug discovery method in years to come and you and your organisation should be part of it.
For more information, kindly visit :
http://www.bharatbook.com/
______________________________________________
